NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's Stock Manipulation Allegations Featured in CTV News W5 Series
TL;DR
Quantum BioPharma's $700 million lawsuit and $7 million reward offer against market manipulation could create significant shareholder value if successful.
Quantum BioPharma alleges stock spoofing by CIBC and RBC in a lawsuit, with a $7 million reward for information leading to judgment or settlement.
Quantum BioPharma's commitment to advancing MS research through Lucid-MS aims to improve treatments for neurodegenerative disorders and protect shareholder interests.
CTV News' W5 program featured Quantum BioPharma's allegations of stock spoofing, highlighting rising market manipulation cases in Canada.
Found this article helpful?
Share it with your network and spread the knowledge!
The content covers Quantum BioPharma's appearance in CTV News' W5 investigative series, which examines the company's allegations of stock spoofing related to its $700 million lawsuit against CIBC and RBC, as well as the company's business operations and research focus.
Quantum BioPharma was featured because the W5 program was investigating the company's allegations of stock manipulation tied to its $700 million lawsuit against CIBC and RBC, as part of a series examining rising market-manipulation cases in Canada.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
Lucid-MS is Quantum BioPharma's lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models, developed through the company's subsidiary Lucid Psycheceuticals Inc.
Co-Executive Chair Anthony Durkacz has offered up to $7 million for information leading to a final judgment or settlement in the litigation related to the stock manipulation allegations.
unbuzzd(TM) is a product invented by Quantum BioPharma that was spun out to Unbuzzd Wellness Inc.; Quantum retains 20.11% ownership (as of March 31, 2025), receives 7% royalties on sales until payments total $250 million (then 3% in perpetuity), and keeps 100% rights for pharmaceutical/medical uses.
The latest news and updates relating to QNTM are available in the company's newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
CEO Zeeshan Saeed reaffirmed the company's commitment to defending shareholders and advancing MS research, while Co-Executive Chair Anthony Durkacz offered financial incentives for information related to the litigation.
Curated from InvestorBrandNetwork (IBN)
